Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

DKK 2016 | Treatment of lymphoma: Overview of the continued progress

Lorenz Trümper • 25 Feb 2016
DKK 2016
Non-Hodgkin Lymphoma T-Cell Lymphoma Ibrutinib Idelalisib

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Lorenz Trümper, MD, from University Hospital of Göttingen, Göttingen, Germany, discusses significant advances in the treatment of lymphoma, including approaches that decrease the toxicity and increase the efficacy of chemotherapy; and approaches that reduce the use of chemotherapy, such as monoclonal antibodies and chimeric antigen receptor (CAR) T-cell therapy.

More from Lorenz Trümper

2:15
Precision medicine for lymphoma: Defining the individual patient
Lorenz Trümper • 25 Feb 2016

Related Videos

1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
1:48
Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing
Gloria Iacoboni • 15 Apr 2024
2:09
Using lineage tracing to define responding CAR T-cells in patients with LBCL
Zinaida Good • 9 Apr 2024
4:34
Access to CAR-T in minority patients with lymphoma in the US: a retrospective analysis
Marco Ruella • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals